Skip to main content
Clinical Trials/NCT01638299
NCT01638299
Completed
Phase 1

Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia and Hyperglycemia in Patients With Type 1 Diabetes in a Clinical Research Setting

Animas Corporation2 sites in 1 country20 target enrollmentJuly 2012

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Type 1 Diabetes Mellitus
Sponsor
Animas Corporation
Enrollment
20
Locations
2
Primary Endpoint
Evaluation of the performance of the HHM system response to meal insulin while the subject is under close medical supervision in the Clinical Research Center (CRC) setting.
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

Feasibility study assessing the ability of an insulin pump-controlling algorithm to minimize hypoglycemia and hyperglycemia in patients with type 1 diabetes in a clinical research setting.

Detailed Description

This study is a non-randomized, uncontrolled feasibility study that looks to enroll people with type 1 diabetes who are currently using an insulin pump. During the subject's participation, the study staff will closely monitor the study subject in a clinical research center environment for approximately 30 hours, while controller algorithm determined insulin doses are delivered by an insulin pump, and utilizing continuous glucose monitoring results.

Registry
clinicaltrials.gov
Start Date
July 2012
End Date
September 2012
Last Updated
13 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age 21-65 years
  • type 1 diabetes mellitus for at least one year
  • Currently using an insulin infusion pump for at least the past 6 months

Exclusion Criteria

  • Pregnancy
  • History of Diabetic Ketoacidosis (DKA) in the past six months
  • Histoey of severe hypoglycemia (Seizure, unconsciousnesss) in the past 6 months

Outcomes

Primary Outcomes

Evaluation of the performance of the HHM system response to meal insulin while the subject is under close medical supervision in the Clinical Research Center (CRC) setting.

Time Frame: After subject is discharged from CRC, 1 week after enrolment

Secondary Outcomes

  • Number of Safety Events and any additional information that can be used for product development(After subject is discharged from CRC, 1 week after enrolment)

Study Sites (2)

Loading locations...

Similar Trials